![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Evaluating utilization and management of comedications with potential for drug-drug interactions among patients with chronic hepatitis C initiating treatment with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
|
|
|
EASL 2023 june 21-24 vienna
Stuart Gordon1, Andrea Steffens2, Laura Weber2, Kimberly McNiff2, Alon Yehoshua3
1Henry Ford Hospital, Detroit, MI, USA; 2HEOR, Optum Life Science, Eden Prairie, MN, USA 3HEOR Liver Disease, Gilead Sciences, Foster City, CA, USA
![0630231](../images/063023/063023-26/0630231.gif)
![0630232](../images/063023/063023-26/0630232.gif)
![0630233](../images/063023/063023-26/0630233.gif)
![0630234](../images/063023/063023-26/0630234.gif)
![0630235](../images/063023/063023-26/0630235.gif)
![0630236](../images/063023/063023-26/0630236.gif)
![0630237](../images/063023/063023-26/0630237.gif)
![0630238](../images/063023/063023-26/0630238.gif)
![0630239](../images/063023/063023-26/0630239.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|